LAVIPHARM S.A. NA EO 1 Asset Resilience Ratio
LAVIPHARM S.A. NA EO 1 asset resilience ratio. LAVIPHARM S.A. NA EO 1 (BXA0) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LAVIPHARM S.A. NA EO 1 defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of LAVIPHARM S.A. NA EO 1 (2022–2023)
Asset resilience ratio of LAVIPHARM S.A. NA EO 1 from 2022 to 2023. This chart shows how LAVIPHARM S.A. NA EO 1's Asset Resilience Ratio has changed over time. Read BXA0 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down LAVIPHARM S.A. NA EO 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BXA0 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.00K | 0.0% |
| Total Liquid Assets | €3.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LAVIPHARM S.A. NA EO 1 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LAVIPHARM S.A. NA EO 1 Industry Peers by Asset Resilience Ratio
Compare LAVIPHARM S.A. NA EO 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
LAVIPHARM S.A. NA EO 1 Asset Resilience Ratio by Year (2022–2023)
LAVIPHARM S.A. NA EO 1 asset resilience ratio by year from 2022 to 2023. The table below shows the annual Asset Resilience Ratio data for LAVIPHARM S.A. NA EO 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | €3.00K ≈ $3.51K |
€114.79 Million ≈ $134.20 Million |
+0.00pp |
| 2022-12-31 | 0.00% | €1.00K ≈ $1.17K |
€114.17 Million ≈ $133.47 Million |
-- |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more